Pfizer (NYSE:PFE) draws attention as low-multiple pharmaceutical names feature in value-oriented conversations during a ...

Pfizer (NYSE:PFE) draws attention as raised revenue guidance, non-COVID strength, and an expanding obesity program frame its ...

Pfizer's non-COVID-19 portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth ...

Pfizer's stock has fallen more than 50% from its 2021 high. The stock is trading below its pre-coronavirus pandemic level. Pfizer is dealing with what are, in reality, just normal headwinds in the ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Late in 2023 I believed that the potential was still there in the case of Pfizer (PFE) after another setback in the pipeline. To see where Pfizer comes from, we really have to create some perspective, ...

Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion and ...

Pfizer(NYSE: PFE) was founded in 1849. That makes the company well over 100 years old. Not many companies have managed to survive as long as Pfizer has, especially in an industry as highly technical ...